^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GB-13

    i
    Other names: GB-13
    Associations

    News

    Trials
    Company:
    Targepeutics
    Drug class:
    IL-13 antagonist
    Related drugs:
    Associations

    News

    Trials
    over2years
    Efficacy of convection-enhanced delivery of GB-13 (IL13.E13K-PE4E) in an orthotopic xenograft model of high-grade glioma is predicated on IL-13Rα2 expression. (ISPNO 2022)
    No abstract available
    Preclinical
    |
    IL13 (Interleukin 13)
    |
    GB-13
    over2years
    Efficacy of convection-enhanced delivery of GB-13 (IL13.E13K-PE4E) in an orthotopic xenograft model of high-grade glioma is predicated on IL-13Rα2 expression. (ISPNO 2022)
    No abstract available
    Preclinical
    |
    IL13 (Interleukin 13)
    |
    GB-13
    over2years
    IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. (PubMed, Pharmaceutics)
    In adults, glioblastoma (GBM) remains largely intractable, with a median survival of approximately 14 months despite standard clinical care of radiation and temozolomide...Direct intratumoral administration of GB-13 via convection-enhanced delivery (CED) significantly decreased tumor burden and resulted in prolonged survival in IL-13Rα2-upregulated orthotopic xenograft models of HGG. In summary, administration of GB-13 demonstrated a promising pharmacological response in HGG models both in vitro and in vivo in a manner strongly associated with IL-13Rα2 expression, underscoring the potential of this IL-13Rα2-targeted therapy in a subset of HGG with increased IL-13Rα2 levels.
    Journal
    |
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • IL13 (Interleukin 13)
    |
    temozolomide • GB-13